Antibody-oligonucleotide bioconjugates with highly-controlled degree of labelling
Thiol-re-bridging technology with ETAC chemistry addresses DOL control and bioconjugate size issues in DNA-PAINT, enhancing imaging quality and resolution by attaching oligonucleotides away from the antigen-binding region.
Patent Information
- Application Number
- PCT/EP2026/064157
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-15
- Filing Date
- 2026-05-14
- Publication Date
- 2026-11-19
AI Technical Summary
Current methods for producing antibody-oligonucleotide bioconjugates for DNA-PAINT microscopy lack control over the degree of labelling (DOL), bioconjugate size, and specificity of oligonucleotide attachment, leading to suboptimal imaging quality and resolution.
A method using thiol-re-bridging technology with ETAC chemistry to introduce oligonucleotides at disulfide bonds of antibodies, minimizing stochastic labelling and attaching them away from the antigen-binding region, resulting in bioconjugates with a controlled DOL of 1 and reduced interference.
Produces bioconjugates with well-defined blinking properties and homogeneous brightness, enabling high-resolution DNA-PAINT imaging by minimizing linkage errors and maintaining antigen-binding functionality.
Smart Images

Figure EP2026064157_19112026_PF_FP_ABST
Abstract
Description
ANTIBOD Y-OLIGONUCLEOTIDE BIOCONJUGATES WITH HIGHLY-CONTROLLED DEGREE OF LABELLING
[0001] The invention is directed to a bioconjugate for use in DNA-PAINT super-resolution microscopyBACKGROUND
[0002] The DNA-PAINT technique (DNA points accumulation for imaging in nanoscale topography) allows single-molecule resolution microscopy using antibody-oligonucleotide bioconjugates. Antibody binders are conjugated to oligonucleotide “docking” strands, which act as binding partners for fluorescent dye-labelled “imaging” strands. The associationdissociation interaction between docking and imaging strands results in transient, localized fluorescent signals (“blinks”), which mark discreet antibody binding sites. Accumulation of data from many such blinks allows precise localization of the binding site with subdiffraction-limited spatial resolution, typically between 1 and 10 nm.
[0003] A major limitation in the field of DNA-PAINT is the availability of high-quality antibody-oligonucleotide conjugates.
[0004] An important characteristic of DNA-PAINT bioconjugates is their degree of labelling (DOL), i.e. the number of oligonucleotides per antibody (Ab) or antibody-fragment (e.g. Fab, VHH). The goal is to produce Ab-oligo bioconjugates with exactly one oligonucleotide per antibody and with low levels of unmodified Ab. Such bioconjugates produce well-defined blinking, homogeneous brightness and blinking frequency, and allow the highest imaging quality. Additionally, blinking frequency can be potentially used as a multiplexing parameter, allowing simultaneous labeling with different specificities to be distinguished by differential kinetics of distinct docking-imaging strand pairs (Wade et al., Nano Lett. 2019, 19(4), 2641). Such frequency multiplexing relies on bioconjugates with tightly-controlled DOL.
[0005] A second important characteristic is the overall bioconjugate size. Larger bioconjugates display greater so-called “linkage errors”, which limit the achievable resolution. In this regard, bioconjugates made without the use of long linkers or bulky nonantibody protein constituents, are preferable. Finally, it is preferrable to label antibodies at positions that avoid interference of the conjugated oligonucleotide with the antigen binding region. This is typically difficult to ensure when using abundant amino acid residues, such as lysine, as conjugation handles.
[0006] The combination of these three characteristics - good DOL control, small size and avoidance of the antigen-binding region - has proved challenging. Easy, purely chemical methods, not requiring extra enzymes or engineered conjugation handles, is currently lacking. Here we provide a technical solution to this problem, which offers a means to synthesize antibody-oligonucleotide conjugates with a single oligonucleotide modification, using purely chemical methods, not requiring genetically-induced antibody alterations, and which attaches the oligonucleotide at a site distinct from the antigen-binding region.OBJECT OF THE INVENTION
[0007] The method of the invention uses so-called thiol-re-bridging technology to introduce an oligonucleotide modification at a disulfide bond of an antibody, thus addressing the above-mentioned limitations of the prior art.
[0008] Object of the invention is therefore a method for providing an antigen recognizing moiety Y having at least one disulfide group with an oligonucleotide characterized in that a) the least one disulfide group of the antigen recognizing moiety Y is reduced to at least two thiol groups andb) the thus obtained antigen recognizing moiety Y having at least two thiol groups is reacted with compound (II)HN-R3QJ)with R1 = substituted or unsubstituted aromatic residues;R2 = H, F, NO2, alkyl with 1 to 5 carbon atoms;R3: oligonucleotide having 10-50 nucleotideswithin at most 60 minutes of reaction time, like in 10 to 60 minutes.
[0009] The method of the invention minimizes susceptibility to stochastic labelling by utilizing a conjugation handle (disulfide bond) that is less abundant than either lysine or (single) cysteine residues. Consequently, our method produces bioconjugates with one modification per an antibody (i.e. DOL = 1), minimizing loss to higher-DOL species and simplifying purification.
[0010] Preferable, step b) is performed with in 10 to 40 minutes of reaction time.
[0011] Further advantages are:A) Minimizing modification near the antigen-binding region. On IgGl antibodies (used here), two interchain disulfide bonds, connecting light chain (LC) and heavy chain (HC) subunits, are most susceptible to reduction. These bonds are far-removed from the antigen-binding region and represent the primary location of oligonucleotide addition in the current method.B) Directly transferable to bioconjugation of antibody fragments (Fabs), and nanobodies, which offer additional resolution benefits in super-resolution microscopy due to their small size (15 kDa and 50 kDa for Fabs and nanobodies, respectively, compared to 150 kDa for IgGs).C) Resistance (in comparison to e.g. maleimide coupling) to reverse reaction in which the oligonucleotide is lost from the bioconjugate.BRIEF DESCRIPTION OF THE DRAWINGS
[0012] Fig 1 shows the general mechanism of bioconjugation using ETAC chemistry. The disulfide bond on the protein is reduced and subsequently reacted with the base-activated ETAC linker. Two consecutive Michael-like additions yield the disulfide “re-bridged” conjugate. Rx and Ry stand for alkyl or aryl residues.
[0013] Fig 2 shows the synthesis scheme for production of antibody-oligonucleotide bioconjugates using ETAC chemistry (Equilibrium Transfer Alkylation Cross-linking). Top: The oligonucleotide (R3) is first activated by reaction with the ETAC linker. Bottom: In parallel, a pair of proximal thiol groups is produced by disulfide bond reduction. The activated oligonucleotide intermediate is then added, producing the desired IgG-oligonucleotide conjugate by re-bridging of the proximal thiols.
[0014] Fig 3 shows the optimization of oligonucleotide activation with ETAC linker.
[0015] Fig 4 shows the chromatographic purification of an IgG-oligonucleotide bioconjugate made using ETAC chemistry. Depicted is the separation of desired product (IgG + 1 oligo), minor side products (IgG + 2 oligos, IgG + 3 oligos), as well as IgG and oligonucleotide (oligo) starting materials.
[0016] Fig 5 shows the characterization of the resulting antibody-oligonulceotide bioconjugate by a) UV-vis spectroscopy and b) analytical size-exclusion chromatography (SEC). The UV-vis data demonstrates that the absorbance spectrum of the bioconjugate lies directly between those of the antibody and oligonucleotide starting materials, as would beexpected for a single oligonucleotide modification. The SEC data shows the shift in retention time resulting from oligonucleotide modification of the antibody (~20 s).
[0017] Fig 6 shows DNA-PAINT super-resolution imaging using IgG-oligonucleotide conjugates that were made using ETAC chemistry. Single molecule-resolution images depicting expression of a) human CD8 in CHO (chinese hamster ovary) cells, b) human PD-1 (CD279) in CHO cells, c) human CD45 in Jurkat cells, and d) human CD3 in Jurkat cells. Each image shows one full cell.DETAILED DESCRIPTION
[0018] The invention uses ETAC chemistry, a form of thiol re-bridging technology, to create antibody IgG-oligonuleotide bioconjugates with well-defined and highly-controlled DOLs, particularly DOL = 1, which is a major advantage for DNA-PAINT applications.
[0019] Our approach involves activation of an amine-modified oligonucleotide with an N- succidimidyl-subsituted ETAC linker (compound III). The linker-activated oligonucleotide then forms a reactive intermediate (II) that can be coupled to a reduced antibody. During this coupling, the proximal thiol functional groups liberated by disulfide reduction are reconnected (“re-bridged”) via the intermediate (II), thereby incorporating the oligonucleotide. Figure 1 shows the mechanism by which ETAC-mediated thiol re-bridging occurs. The general conjugation strategy for synthesis of IgG-oligonucleotide conjugates using ETAC chemistry is shown in Figure 2.
[0020] In the method of the invention, compound (II) is preferable obtained by reacting compound (III) with an oligonucleotide R3 comprising 10-50 nucleotides and having at least one ammo groupwith R2 = H, F, NO2, alkyl with 1 to 5 carbon atoms;
[0021] The chemical nature or the sequence of the oligonucleotide R3 is not of particular importance, but R3 is preferable provided with at least one amino group introduced as a 5’ end, 3’ end or as internal modification.
[0022] Similar, chemical nature or the sequence the antigen recognizing moiety Y is not of particular importance, but Y should be selected according to the target protein that is to be bound by the antigen recognizing moiety Y. The antigen recognizing moiety Y may by selected from the group consisting of antibodies, immunoglobulins, antigen-binding fragments (Fabs), single-domain antibodies and nanobodies as long as they contain a disulfide bridge.
[0023] In the method of the invention, the least one disulfide group of the antigen recognizing moiety Y is preferable reduced to at least two thiol groups by tris(3-hydroxypropyl)phosphine (THPP) or other reducing agents such as tris(2-carboxyethyl)phosphine (TCEP) or dithiothreitol (DTT).USE OF THE CONJUGATES
[0024] The conjugates according to the invention or as obtained by the method of the invention are due to the controlled DOL particular useful in a of DNA-PAINT type of imaging process.
[0025] Further object of the invention is therefore the use (or a method of using) of a conjugate according to formula (I)with R2 = H, F, NO2, alkyl with 1 to 5 carbon atoms;R3: oligonucleotide having 10-50 nucleotides.Y : antigen recognizing moietyin a method for detecting a target protein in a sample by fluorescence imaging characterized ina) providing the conjugate according to formula (I) with at least one at least one image strand comprising a fluorescence moiety and an oligonucleotide having at least in part the complementary sequence of the oligonucleotide R3 of the conjugate,b) binding of the target protein by the antigen recognizing moiety Y of the conjugate c) at least transiently binding the oligonucleotide of the image strand to the oligonucleotide R3 of the conjugate andd) detecting fluorescence radiation resulting from the excitation of the fluorescence moiety with light.
[0026] Preferable, the oligonucleotide of the image strand comprises 4 to 10 nucleotides.
[0027] The conjugate (I) (i.e. the oligonucleotide R3 of the conjugate (I)) and the oligonucleotide of the imager strand are preferable transiently bound to each other for 1 to 10 s.EXAMPLES
[0028] In the following sections we describe:1) the experimental protocol for IgG-oligonucleotide conjugation using the Compound (III)2) necessary optimization of reaction conditions allowing successful production of DNA- PAINT conjugates via Compound (III)3) a summary of the IgG- and Fab-oligonucleotide bioconjugates produced4) characterization of the antibody-oligonucleotide bioconjugates
[0029] Experimental protocol for IgG-oligonucleotide conjugation using the Compound (III) linker
[0030] Two 5’ amine-modified oligonucleotides were used: oligo 1 (19 nucleotides) and oligo 2 (25 nucleotides). Compound (III) was stored at 4 mg / mL in anhydrous dimethylsulfoxide (DMSO) at -20 °C under inert atmosphere.
[0031] Recombinant IgGls (REAs) were reduced using 3 molar equivalents of tris(hydroxypropyl)phosphine (THPP) (1 hr, room temp, with agitation) and used without purification.
[0032] Amine-modified oligonucleotides (~70 pM) were incubated with 17 equivalents of compound (III) (linker) for 30 min at pH 9 (PBS + 5 mM EDTA + 50 mM sodium carbonate buffer) with strong agitation. The reaction mixture contained -15% DMSO by volume. Excess compound (III) was removed by gel filtration and the concentration of the purified activated oligonucleotide was determined by UV spectroscopy (260 nm).
[0033] To the reduced antibody was added 5 molar equivalents of activated oligonucleotide (in PBS + 5 mM EDTA, pH 7.8). The solution was incubated overnight at room temperature with agitation.
[0034] The IgG-oligonucleotide conjugate was purified by fast protein liquid chromatography (FPLC) on a TOYOPEARL GigaCap Q-650M anion exchange column. The purified bioconjugate was rebuffered in PBS + 5 mM EDTA, pH 7.8, supplemented with 0.1% HSA and 0.05% sodium azide and stored at 4 °C.
[0035] Figure 3 shows a representative chromatogram from purification of IgG-oligonucleotide bioconjugate produced by the above method with : A) At various time points after initiation of oligonucleotide activation, the oligonucleotide (oligo 1) was purified and reacted with 20 equivalents of dithiothreitol (DTT). The amount of activated oligonucleotide was estimated by the amount of DTT-oligonucleotide conjugate formed. B) The amount of DTT-conjugate (inverted triangles) decreased with increasing activation time, being replaced by non-DTT-reactive side products (squares). The levels of unreacted oligonucleotide were similar across all time points (triangles). The 30 min time point was chosen as the optimal balance between unreacted oligonucleotide and activated oligonucleotide available for IgG coupling. C) Anion exchange chromatograms showing that decreasing the oligonucleotide activation time results in a greater efficiency of antibody coupling, shown here with the an anti-CD45 antibody (clone RE1023) and oligo 1.
[0036] Table 1 shows a summary of the various IgG- and Fab-oligonucleotide bioconjugates produced and their measured DOLs. DOLs were highly consistent across seven specificities, two binder types (IgG and Fab) and two different oligonucleotide sequences.
[0037] Conjugates were characterized by UV-Vis spectroscopy, analytical size-exclusion chromatography (SEC) and mass spectrometry, and tested in the DNA-PAINT application. UV-Vis data was used to calculate the DOL. Analytical SEC chromatography was used to both determine the purity of the conjugate and assess the retention time changes indicative of successful conjugation (i.e. shorter retention time for conjugate compared to pure IgG). Mass spectrometry was used to confirm the presence of the expected product molecular weight.
[0038] The DOL was calculated using the absorbance at 280 nm and 260 nm according to the following equation(260 260 \
[0039] DOL =e280 Ab^8°con^j0Ab)I zsoconje260 oligo\ 1” 260\ 280oligoWhere:£280 Ab = molar extinction coefficient of antibody at 280 nm£260 oligo = molar extinction coefficient of oligonucleotide at 260 nm260 / 280conj = ratio of 260 nm to 280 nm absorbance of the conjugate260 / 280Ab = ratio of 260 nm to 280 nm absorbance of the antibody260 / 280oiigo= ratio of 260 nm to 280 nm absorbance of the oligonucleotideNecessary optimization of reaction conditions allowing successful production of DNA- PAINT conjugates via Compound (III)
[0040] Liquid chromatography mass spectrometry (LC-MS) was used to optimize activation of oligonucleotide with the ETAC linker and facilitate efficient downstream coupling to the antibody. The amine-modified oligonucleotide was mixed with excess ETAC linker (17 molar equivalents) in PE buffer with 5 mM ETDA, adjusted to pH 9 using 500 mM carbonate buffer. After 30 min., 3 h, 6 h or overnight reaction, the activated oligonucleotide was purified by gel filtration using Sephadex G25 resin (NAP-5 or PD-10 column). To the purified, activated oligonucleotide was added 20 molar equivalents of dithiothreitol (DTT) in PBS with 5 mM EDTA. DTT served as a rapidly-reacting probe molecule to assess the degree of oligonucleotide activation by the ETAC linker. After overnight incubation, excess DTT was removed by gelfiltration on a Sephadex G25 column pre-equilibrated with nuclease-free water. The purified DTT-oligonucleotide product was injected directly into the nebulizer of the mass spectrometer (Compact QTOF, Bruker). In the resulting mass spectrum, the main mass peaks, corresponding to the desired DTT-oligonucleotide product as well as several unwanted side-products, were integrated and used to determine the optimal oligonucleotide activation time (see Figure). In a separate experiment, antibody partially reduced with 3 molar equivalents of THPP, was incubated in situ with oligonucleotide activated with the optimized reaction time determined as above. The results of these experiments are depicted in Figure 3. The optimal oligonucleotide activation time was found to be 30 min. Furthermore, the efficiency of conjugation to antibody was higher with this optimized activation time than with oligonucleotide activated overnight.
[0041] The following table 1 shows the characteristics of IgG- and Fab-oligonucleotide conjugates produces. The conjugation procedure results in conjugates with hi ghly-consi stent DOLs, independent of which antibody or oligonucleotide is used. Abbreviations: 260 / 280Ab, 260 / 280oiigoand 260 / 280COnj are the ratio of absorbance at 260 nm to 280 nm of the antibody, oligonucleotide and bioconjugate, respectively. All antibodies are available from Miltenyi Biotec BV&Co KG.Antibody Type Oligo 260 / 280Ab 260 / 280oiigo 260 / 280conj DOL PD-1 REA838 IgG Oligo 1 0.51 2.25 1.01 1.0 CD25 REA570 IgG Oligo 1 0.53 2.25 1.00 0.9 CD28 REA612 IgG Oligo 1 0.51 2.25 1.05 1.1 CD8 REA734 IgG Oligo 1 0.51 2.25 1.06 1.1 p-LAT REA160 IgG Oligo 1 0.51 2.25 0.96 0.9 CD54 REA266 IgG Oligo 1 0.51 2.25 0.94 0.8 CD2 REA972 IgG Oligo 2 0.54 2.17 1.09 0.9 CD28 REAL 105 FAb Oligo 2 0.48 2.17 1.49 1.0 CD3 REAL 104 FAb Oligo 2 0.49 2.17 1.47 1.0
[0042] Analytical SEC (Figure 4b) confirmed both the purity of the conjugates, which were free from unconjugated oligonucleotides, as well as the retention time shift, with the conjugate eluting ~20 s later than the unconjugated IgG. The presence of desired single oligonucleotide modification was confirmed by UV-vis spectroscopy (see Table 1 and Figure 4a) as well as the mass spectra of the conjugates.
Claims
CLAIMS1. Method for providing an antigen recognizing moiety Y having at least one disulfide group with an oligonucleotide characterized in thata) the least one disulfide group of the antigen recognizing moiety Y is reduced to at least two thiol groups andb) the thus obtained antigen recognizing moiety Y having at least two thiol groups is reacted with compound (II)with R1 = substituted or unsubstituted aromatic residues;R2 = H, F, NO2, alkyl with 1 to 5 carbon atoms;R3: oligonucleotide having 10-50 nucleotides.within at most 60 minutes of reaction time.
2. Method according to claim 1 characterized in that compound (II) is obtained by reacting compound (III)with an oligonucleotide R3 having at least one amino group.
3. Method according to claim 1 or 2 characterized in that the oligonucleotide R3 is provided with at least one amino group introduced as a 5’ end, 3’ end or internal modification.
4. Method according to any of claims 1 to 3 characterized in that the least one disulfide group of the antigen recognizing moiety Y is reduced to at least two thiol groups by tris(3-hydroxypropyl)phosphine (THPP) or other reducing agents such as tris(2- carboxyethyl)phosphine (TCEP) or dithiothreitol (DTT).
5. Method according to any of claims 1 to 4 characterized in that the antigen recognizing moiety Y is selected from the group consisting of antibodies, immunoglobulins, antigenbinding fragments (Fabs), single-domain antibodies and nanobodies.
6. Use of a conjugate according to formula (I)with R2 = H, F, NO2, alkyl with 1 to 5 carbon atoms;R3: oligonucleotide having 10-50 nucleotides.Y : antigen recognizing moietyin a method for detecting a target protein in a sample by fluorescence imaging characterized ina) providing the conjugate according to formula (I) with at least one at least one image strand comprising a fluorescence moiety and an oligonucleotide having at least in part the complementary sequence of the oligonucleotide R3 of the conjugate, b) binding of the target protein by the antigen recognizing moiety Y of the conjugate c) at least transiently binding the oligonucleotide of the image strand to the oligonucleotide R3 of the conjugate andd) detecting fluorescence radiation resulting from the excitation of the fluorescence moiety with light.
7. Use according to claim 7 characterized in that the conjugate (I) and the oligonucleotide of the imager strand are transiently bound to each other for 1 to 10 s.
8. Use according to claim 8 or 7 characterized in that the oligonucleotide of the image strand comprises 4 to 10 nucleotides.
